CalciMedica Inc
Company Profile
Business description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Contact
505 Coast Boulevard South
Suite 307
La JollaCA92037
USAT: +1 858 952-5500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,928.00 | 51.40 | -0.57% |
CAC 40 | 7,818.28 | 32.15 | -0.41% |
DAX 40 | 24,295.93 | 55.11 | 0.23% |
Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
FTSE 100 | 9,138.37 | 76.88 | 0.85% |
HKSE | 25,441.03 | 226.15 | -0.88% |
NASDAQ | 21,057.96 | 37.94 | 0.18% |
Nikkei 225 | 41,461.40 | 364.94 | -0.87% |
NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
S&P 500 | 6,363.35 | 4.44 | 0.07% |
S&P/ASX 200 | 8,659.70 | 49.70 | -0.57% |
SSE Composite Index | 3,597.30 | 8.42 | -0.23% |